Japan's Healios Progresses Novel Cell Therapy For ARDS
Activity in Japan's cell and regenerative therapy space continues apace as venture starts trial with lead development asset for acute respiratory distress syndrome.
You may also be interested in...
While COVID-19 shocked global financial markets and is expected to impact biopharma fundraising, investment in drug developers continues, including through two new venture capital funds totaling nearly $2bn. Also, Coherus issues debt to fund deals and MOMA launches with $86m in VC cash.
Coronavirus Update: More Companies Join Therapeutics Accelerator, FDA Delays AdCom For First NASH Drug
As the global number of COVID-19 cases exceeds 500,000 for the first time, more biopharma companies throw their weight behind Gates Foundation's drug-hunting initiative.
Big pharma partner takes on prime development responsibility for novel AMD cell therapy as Japanese venture concentrates resources on other in-progress trials.